Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Apple and Masimo have been engaged in tit-for-tat ... litigation between the two companies focusing on the use of pulse oximetry sensors in some Apple Watches, which resulted in a temporary ...

With President-elect Donald Trump proposing tariffs as high as 60%- 100% on goods imported from China, Wall Street analysts ...

Additionally, the Blood Oxygen app remains disabled due to an import ban that says Apple infringed on a SpO2 sensor patent owned by health tech company Masimo. Sign up to get the BEST of Tom's ...

The conversion ensures that all multiparameter patient monitors, stand-alone oximeters, and sensors throughout the hospital ... the new technology platform hospital-wide with Masimo SET pulse oximetry ...

Note that the Masimo trade secret lawsuit against Apple is separate from both an ITC injunction preventing the sale of Apple ...

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and ...

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ETCompany ParticipantsEli Kammerman - VP of Business ...